Examines IgA antibody responses in blood, saliva, and tears post SARS-CoV-2 exposure and vaccination, suggesting variability in mucosal immunity.
Introduction To determine whether anti-SARS CoV-2 IgA responses in blood reflected the expression of anti-SARS CoV-2 IgA in mucosal tissues, anti-SARS-CoV-2 IgA antibodies in blood plasma, tears and saliva were measured by indirect ELISA before and after SARS-CoV-2 exposure or COVID-19 vaccination. Methods SARS-CoV-2 RBD of Wuhan (R&D Systems; Cat #10534CV) or Omicron (Proteogenix; PX-CoV-P080) were used to coat ELISA plates. Blood, tear or saliva specimens were added at 1:100, 1:40, and 1:5 dilutions respectively. Human anti-SARS-CoV-2 RBD (Wuhan) IgA monoclonal antibody (Proteogenix; Cat # PTXCOV-569) was used as a standard to determine the concentration of anti-SARS-CoV-2 RBD IgA antibody . Results Blood plasma was available from fourteen individuals before and after SARS-CoV-2 exposure or COVID-19 vaccination. Seroconversion for anti-SARS-CoV-2 IgG antibodies was observed in all individuals whereas only six of fourteen (43%) demonstrated anti-SARS-CoV-2 IgA antibodies. In a larger cohort of 39 participants that were anti-SARS-CoV-2 RBD IgG positive, 16 (41%), 9 (23%), and 11(28%) were positive for anti-SARS-CoV-2 RBD IgA in blood, saliva and tears respectively. Forty four percent of individuals positive for anti-SARS-CoV-2 RBD IgA in blood were also IgA positive in saliva or tears. Thirty percent of individuals negative for anti-SARS-CoV-2 RBD IgA in blood were IgA positive in saliva or tears. In a pilot study three individuals with anti-SARS-CoV-2 IgA antibodies directed against Wuhan and Omicron variants demonstrated anti-SARS-CoV-2 IgA antibodies in the tears from both eyes. Conclusion Our data indicate that anti-SARS-CoV-2 IgA responses in blood, tears, and saliva are variable in SARS-CoV-2 exposed and COVID-19 vaccinated individuals with discordant responses in blood and mucosal tissues. Equivalent antibody responses in tears of both eyes suggests equal seeding of both lacrimal glands by antibody-producing B cells. Funding Source Franciscan Institute of Science and Health Topic Categories Mucosal and Regional Immunology (MUC)
No takes yet. Share an insight, caveat, or question.
McKenna et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: